3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 4-(3-aminophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 4-(3-aminophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
• 英文别名: NS4-238；3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 4-(3-aminophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
• 化学式: C₂₇H₃₀N₂O₅
• 分子量: 462.546
• InChiKey: ZXNCTLOWNQOIBI-DHZHZOJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  99.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  cilnidipine 在 铁粉 、 溶剂黄146 作用下， 反应 0.25h， 以78%的产率得到3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 4-(3-aminophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
  参考文献：
  名称：

  [EN] Drp1-FILAMIN COMPLEX FORMATION INHIBITORS
  [FR] INHIBITEURS DE FORMATION DE COMPLEXE DRP1-FILAMINE

  摘要：

  由下式（I）表示的化合物及其药理学上可接受的盐和溶剂化物；含有它们的药物组合物和动态蛋白相关蛋白1（Drp1）-filamin复合物形成抑制剂；以及用于作为预防或治疗剂的化合物、盐、溶剂化物、药物组合物和（Drp1）-filamin复合物形成抑制剂。

  公开号：

  WO2020241638A1

文献信息

• Drp1-FILAMIN COMPLEX FORMATION INHIBITORS
  申请人：RDISCOVERY, LLC

  公开号：US20220169613A1

  公开（公告）日：2022-06-02

  Compounds represented by formula (I) below and pharmacologically acceptable salts thereof and solvates of them; pharmaceutical compositions and dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors containing them; and uses of the compounds, salts, solvates, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors for use as a prophylactic or therapeutic agent.
• [EN] 1,4-DIHYDROPYRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE<br/>[FR] COMPOSES DE 1,4-DIHYDROPYRIDINE, COMPOSITIONS PHARMACEUTIQUES ET METHODES DESTINEES AU TRAITEMENT DE MALADIES CARDIOVASCULAIRES
  申请人：MYOGEN INC

  公开号：WO2005042486A1

  公开（公告）日：2005-05-12

  The present invention provides certain substituted 1,4-dihydropyridine compounds, including pure enantiomeric forms and pharmaceutical formulations thereof These compounds provide for elevation of α-MyHC protein levels and α-MyHC mRNA levels, and most frequently these same compounds provide simultaneous lowering of β-MyHC protein levels and β-MyHC mRNA levels. Thus, these compounds may be used alone or in conjunction with other drugs to treat heart failure.
• [EN] THERAPIES FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES<br/>[FR] THÉRAPIES POUR LE TRAITEMENT DU CANCER ET DE MALADIES ASSOCIÉES À UNE DÉFICIENCE EN PHAGOCYTOSE
  申请人：[en]RDISCOVERY, LLC

  公开号：WO2022098642A1

  公开（公告）日：2022-05-12

  Methods for treating diseases and conditions associated with phagocytosis deficiency and methods for treating cancer with phagocytosis activating agents and mitochondrial fission inhibitors, respectively, as monotherapy or in combination with one or more additional agents, and agents, combinations of agents, and compositions for treating diseases and conditions associated with phagocytosis deficiency.
• [EN] Drp1-FILAMIN COMPLEX FORMATION INHIBITORS<br/>[FR] INHIBITEURS DE FORMATION DE COMPLEXE DRP1-FILAMINE
  申请人：UNIV KYUSHU NAT UNIV CORP

  公开号：WO2020241638A1

  公开（公告）日：2020-12-03

  Compounds represented by formula (I) below and pharmacologically acceptable salts thereof and solvates of them; pharmaceutical compositions and dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors containing them; and uses of the compounds, salts, solvates, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors for use as a prophylactic or therapeutic agent.

  由下式（I）表示的化合物及其药理学上可接受的盐和溶剂化物；含有它们的药物组合物和动态蛋白相关蛋白1（Drp1）-filamin复合物形成抑制剂；以及用于作为预防或治疗剂的化合物、盐、溶剂化物、药物组合物和（Drp1）-filamin复合物形成抑制剂。